Wuxi Biologics (Cayman), Inc. is an investment holding company, which provides end-to-end solutions and services for biologics discovery, development, and manufacturing services and manufacturing of biologics products. The company is headquartered in Wuxi, Jiangsu and currently employs 12,552 full-time employees. The company went IPO on 2017-06-13. The firm mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The firm mainly conducts its business in the domestic and overseas markets.
02269.HK stock price ended at $39.26 on 金曜日, after dropping 1.90%
On the latest trading day Jan 16, 2026, the stock price of 02269.HK fell by 1.90%, dropping from $38.66 to $39.26. During the session, the stock saw a volatility of 3.89%, with prices oscillating between a daily low of $38.54 and a high of $40.04. On the latest trading day, the trading volume for 02269.HK rose by 171.7M shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 201.8M shares were traded, with a market value of approximately $162.0B.